Techniques for differentiating human induced pluripotent stem cells (hiPSCs) into cardiomyocytes (hiPSC-CMs) can yield up to 98% purity, yet control over hiPSC-CM fate is lacking. Here, we present a protocol for insulin dosing during the expansion and maturation of hiPSC-derived cardiomyocytes. We describe steps for differentiation, purification, replating, cryopreservation, and thawing. We then detail a procedure for expansion using insulin and Wnt/β-catenin signaling, followed by steps to initiate maturation by either removing insulin completely or adding a low dose of insulin. For complete details on the use and execution of this protocol, please refer to Yuan et al.
Verbueken et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: